|
ASX - By Stock
|
LTP |
Re:
Ann: TGA Provides Regulatory Clearance for SPONTAN Phase II
|
|
VMVarga
|
34 |
3.6K |
0 |
12/12/25 |
| 12/12/25 |
ASX - By Stock
|
34
|
3.6K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: TGA Provides Regulatory Clearance for SPONTAN Phase II
|
|
VMVarga
|
34 |
3.6K |
0 |
12/12/25 |
| 12/12/25 |
ASX - By Stock
|
34
|
3.6K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: TGA Provides Regulatory Clearance for SPONTAN Phase II
|
|
VMVarga
|
34 |
3.6K |
1 |
11/12/25 |
| 11/12/25 |
ASX - By Stock
|
34
|
3.6K
|
1
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: AI Analysis Reveals Efficacy In Severe Stroke Patients
|
|
VMVarga
|
12 |
1.9K |
3 |
11/12/25 |
| 11/12/25 |
ASX - By Stock
|
12
|
1.9K
|
3
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: TGA Provides Regulatory Clearance for SPONTAN Phase II
|
|
VMVarga
|
34 |
3.6K |
1 |
10/12/25 |
| 10/12/25 |
ASX - By Stock
|
34
|
3.6K
|
1
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Release of Restricted Securities from ASX Mandatory Escrow
|
|
VMVarga
|
57 |
7.2K |
0 |
08/12/25 |
| 08/12/25 |
ASX - By Stock
|
57
|
7.2K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Release of Restricted Securities from ASX Mandatory Escrow
|
|
VMVarga
|
57 |
7.2K |
0 |
06/12/25 |
| 06/12/25 |
ASX - By Stock
|
57
|
7.2K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Release of Restricted Securities from ASX Mandatory Escrow
|
|
VMVarga
|
57 |
7.2K |
2 |
05/12/25 |
| 05/12/25 |
ASX - By Stock
|
57
|
7.2K
|
2
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Release of Restricted Securities from ASX Mandatory Escrow
|
|
VMVarga
|
57 |
7.2K |
1 |
05/12/25 |
| 05/12/25 |
ASX - By Stock
|
57
|
7.2K
|
1
|
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Notice of Change of Interests of Substantial Holder - M Azzi
|
|
VMVarga
|
52 |
16K |
0 |
05/12/25 |
| 05/12/25 |
ASX - By Stock
|
52
|
16K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Release of Restricted Securities from ASX Mandatory Escrow
|
|
VMVarga
|
57 |
7.2K |
8 |
03/12/25 |
| 03/12/25 |
ASX - By Stock
|
57
|
7.2K
|
8
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Release of Restricted Securities from ASX Mandatory Escrow
|
|
VMVarga
|
57 |
7.2K |
0 |
03/12/25 |
| 03/12/25 |
ASX - By Stock
|
57
|
7.2K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Release of Restricted Securities from ASX Mandatory Escrow
|
|
VMVarga
|
57 |
7.2K |
0 |
03/12/25 |
| 03/12/25 |
ASX - By Stock
|
57
|
7.2K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
competition
|
|
VMVarga
|
105 |
14K |
3 |
11/11/25 |
| 11/11/25 |
ASX - By Stock
|
105
|
14K
|
3
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
1 |
11/11/25 |
| 11/11/25 |
ASX - By Stock
|
58
|
7.8K
|
1
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
0 |
11/11/25 |
| 11/11/25 |
ASX - By Stock
|
58
|
7.8K
|
0
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
1 |
11/11/25 |
| 11/11/25 |
ASX - By Stock
|
58
|
7.8K
|
1
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
1 |
10/11/25 |
| 10/11/25 |
ASX - By Stock
|
58
|
7.8K
|
1
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
1 |
10/11/25 |
| 10/11/25 |
ASX - By Stock
|
58
|
7.8K
|
1
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
1 |
10/11/25 |
| 10/11/25 |
ASX - By Stock
|
58
|
7.8K
|
1
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
1 |
10/11/25 |
| 10/11/25 |
ASX - By Stock
|
58
|
7.8K
|
1
|
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Xolatryp Achieves Key Clinical Milestone
|
|
VMVarga
|
1.0K |
188K |
2 |
07/11/25 |
| 07/11/25 |
ASX - By Stock
|
1.0K
|
188K
|
2
|
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Xolatryp Achieves Key Clinical Milestone
|
|
VMVarga
|
1.0K |
188K |
0 |
07/11/25 |
| 07/11/25 |
ASX - By Stock
|
1.0K
|
188K
|
0
|
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Xolatryp Achieves Key Clinical Milestone
|
|
VMVarga
|
1.0K |
188K |
0 |
07/11/25 |
| 07/11/25 |
ASX - By Stock
|
1.0K
|
188K
|
0
|
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Xolatryp Achieves Key Clinical Milestone
|
|
VMVarga
|
1.0K |
188K |
1 |
04/11/25 |
| 04/11/25 |
ASX - By Stock
|
1.0K
|
188K
|
1
|
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Xolatryp Achieves Key Clinical Milestone
|
|
VMVarga
|
1.0K |
188K |
1 |
04/11/25 |
| 04/11/25 |
ASX - By Stock
|
1.0K
|
188K
|
1
|
|
|
ASX - By Stock
|
LTP |
Re:
Talk about a falling knife !
|
|
VMVarga
|
349 |
147K |
0 |
04/11/25 |
| 04/11/25 |
ASX - By Stock
|
349
|
147K
|
0
|
|
|
ASX - By Stock
|
NYR |
Re:
Ann: Xolatryp Achieves Key Clinical Milestone
|
|
VMVarga
|
1.0K |
188K |
1 |
31/10/25 |
| 31/10/25 |
ASX - By Stock
|
1.0K
|
188K
|
1
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Investor Presentation
|
|
VMVarga
|
33 |
5.5K |
0 |
31/10/25 |
| 31/10/25 |
ASX - By Stock
|
33
|
5.5K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Investor Presentation
|
|
VMVarga
|
33 |
5.5K |
2 |
30/10/25 |
| 30/10/25 |
ASX - By Stock
|
33
|
5.5K
|
2
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
VMVarga
|
20 |
2.8K |
1 |
29/10/25 |
| 29/10/25 |
ASX - By Stock
|
20
|
2.8K
|
1
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
VMVarga
|
20 |
2.8K |
0 |
29/10/25 |
| 29/10/25 |
ASX - By Stock
|
20
|
2.8K
|
0
|
|
|
ASX - By Stock
|
AGN Biotech |
Re:
News, Articles and interviews
|
|
VMVarga
|
18 |
2.8K |
3 |
21/10/25 |
| 21/10/25 |
ASX - By Stock
|
18
|
2.8K
|
3
|
|
|
ASX - By Stock
|
AGN Biotech |
Re:
News, Articles and interviews
|
|
VMVarga
|
18 |
2.8K |
3 |
21/10/25 |
| 21/10/25 |
ASX - By Stock
|
18
|
2.8K
|
3
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
0 |
18/10/25 |
| 18/10/25 |
ASX - By Stock
|
58
|
7.8K
|
0
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
1 |
17/10/25 |
| 17/10/25 |
ASX - By Stock
|
58
|
7.8K
|
1
|
|
|
ASX - By Stock
|
LTP |
Re:
Chart
|
|
VMVarga
|
272 |
63K |
1 |
17/10/25 |
| 17/10/25 |
ASX - By Stock
|
272
|
63K
|
1
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
0 |
16/10/25 |
| 16/10/25 |
ASX - By Stock
|
58
|
7.8K
|
0
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
0 |
16/10/25 |
| 16/10/25 |
ASX - By Stock
|
58
|
7.8K
|
0
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: Phase 2 Trial Promising Improvements in Functional Outcomes
|
|
VMVarga
|
58 |
7.8K |
0 |
15/10/25 |
| 15/10/25 |
ASX - By Stock
|
58
|
7.8K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: LTR increases LevOmega stake to 43% with $1m investment
|
|
VMVarga
|
68 |
9.2K |
2 |
13/10/25 |
| 13/10/25 |
ASX - By Stock
|
68
|
9.2K
|
2
|
|
|
ASX - By Stock
|
LTP |
Re:
Ann: LTR increases LevOmega stake to 43% with $1m investment
|
|
VMVarga
|
68 |
9.2K |
0 |
13/10/25 |
| 13/10/25 |
ASX - By Stock
|
68
|
9.2K
|
0
|
|
|
ASX - By Stock
|
AGN |
Re:
AGN Media thread
|
|
VMVarga
|
558 |
169K |
0 |
02/10/25 |
| 02/10/25 |
ASX - By Stock
|
558
|
169K
|
0
|
|
|
ASX - By Stock
|
AGN |
Re:
AGN Media thread
|
|
VMVarga
|
558 |
169K |
0 |
02/10/25 |
| 02/10/25 |
ASX - By Stock
|
558
|
169K
|
0
|
|
|
ASX - By Stock
|
AGN |
Re:
AGN Media thread
|
|
VMVarga
|
558 |
169K |
0 |
01/10/25 |
| 01/10/25 |
ASX - By Stock
|
558
|
169K
|
0
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: ASX Small Caps Conference Presentation
|
|
VMVarga
|
48 |
5.7K |
1 |
28/09/25 |
| 28/09/25 |
ASX - By Stock
|
48
|
5.7K
|
1
|
|
|
ASX - By Stock
|
AGN |
Re:
Ann: ASX Small Caps Conference Presentation
|
|
VMVarga
|
48 |
5.7K |
5 |
26/09/25 |
| 26/09/25 |
ASX - By Stock
|
48
|
5.7K
|
5
|
|
|
ASX - By Stock
|
LTP |
Re:
Investors surprised as LTR Pharma, an erectile dysfunction biotech, moves into... omega-3 fish oil
|
|
VMVarga
|
32 |
7.7K |
0 |
24/09/25 |
| 24/09/25 |
ASX - By Stock
|
32
|
7.7K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
competition
|
|
VMVarga
|
105 |
14K |
0 |
21/09/25 |
| 21/09/25 |
ASX - By Stock
|
105
|
14K
|
0
|
|
|
ASX - By Stock
|
LTP |
Re:
competition
|
|
VMVarga
|
105 |
14K |
1 |
21/09/25 |
| 21/09/25 |
ASX - By Stock
|
105
|
14K
|
1
|
|